Recent advances in targeted therapy for cervical cancer have shown promising results, with several studies focusing on molecular targets such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and programmed death-1 (PD-1)/programmed death-ligand 1(PD-L1) pathways [30,31,32]. Here, EGFR is linked to cervical carcinoma.